

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
15 September 2022 (15.09.2022)



(10) International Publication Number  
**WO 2022/192507 A1**

(51) International Patent Classification:

A61K 31/4365 (2006.01) A61P 35/00 (2006.01)  
C07D 495/04 (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/019700

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

10 March 2022 (10.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/159,417 10 March 2021 (10.03.2021) US

(71) Applicant: **MIRATI THERAPEUTICS, INC.** [US/US];  
3545 Cray Court, San Diego, CA 92121 (US).

(72) Inventors: **ANDRES, Patricia**; c/o Mirati Therapeutics,  
Inc., 3545 Cray Court, San Diego, CA 92121 (US). **AL-  
BERT, Ekaterina**; c/o Mirati Therapeutics, Inc., 3545 Cray  
Court, San Diego, CA 92121 (US). **RIGSBEE, Emily**; c/  
o Mirati Therapeutics, Inc., 3545 Cray Court, San Diego,  
CA 92121 (US). **CAO, Zhiwei**; c/o Mirati Therapeutics,  
Inc., 3545 Cray Court, San Diego, CA 92121 (US). **ZHAO,  
Dalian**; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San  
Diego, CA 92121 (US). **ZHANG, Zhonghua**; c/o Mirati  
Therapeutics, Inc., 3545 Cray Court, San Diego, CA 92121  
(US).

(74) Agent: **POLYAKOV, Mark, V.** et al.; Wood, Phillips,  
Katz, Clark & Mortimer, 500 West Madison Street, Suite  
1130, Chicago, IL 60661 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,  
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,  
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,  
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,  
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: CRYSTALLINE SALT OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF

(57) Abstract: The present invention relates to malate salt of a multi-tyrosine kinase inhibitor. In particular, the present invention relates to crystalline forms of the malate salt of multi-tyrosine kinase inhibitor N-(3-fluoro-4-((2-(5-((2-methoxyethyl)amino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-hydroxy succinate (1 : 1), pharmaceutical compositions comprising the crystalline form, processes for preparing the crystalline form and methods of use therefore.

WO 2022/192507 A1